DNTH vs JNJ: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
JNJ is the larger of the two ($615.87B market cap): the incumbent the market prices for continued execution (21.83x forward earnings, beta 0.21). DNTH is the smaller challenger ($3.94B), priced similarly on forward earnings (-15.63x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
DNTH vs JNJ: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DNTH | JNJ | What it tells you |
|---|---|---|---|
| Market cap | $3.94B | $615.87B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -15.63 | 21.83 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.18 | 0.21 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 47% of range | 74% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.37 | 7.24 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how DNTH and JNJ affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DNTH and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DNTH and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Dianthus Therapeutics (DNTH) do?
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing claseprubart (DNTH103), an antibody that selectively blocks the active form of the C1s enzyme in the complement system's classical pathway while leaving the alternative and lectin pathways intact to preserve immune defense. Using half-life-extension (YTE) technology, the drug is designed for infrequent, low-volume subcutaneous self-injection (as seldom as once every four weeks), which the company positions as a convenience advantage over infused or more frequently dosed rivals. The lead programs target rare autoimmune and neuromuscular diseases: chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG), and multifocal motor neuropathy (MMN).
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
DNTH vs JNJ: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- DNTH drivers: Phase 3 CIDP readout (CAPTIVATE); Generalized myasthenia gravis expansion.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue, essentially single-asset company, DNTH faces concentrated clinical risk: a failed or ambiguous Phase 3 readout in CIDP or gMG could sharply reduce the value of the entire pipeline. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.
DNTH or JNJ: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DNTH if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DNTH and JNJ guides.
DNTH vs JNJ: the full fundamentals
DNTH. Standard valuation multiples do not apply because Dianthus has no product revenue and runs at a loss funding clinical trials. The market cap has come down to about $3.9 billion from the roughly $4.8 billion of mid-2026 after a 26% one-month drop, though it is still about 80% higher than at the start of the year. The analyst average target near $141 is about double the October 16 close, so the gap between sell-side and market expectations for the CAPTIVATE readout is wide.
JNJ. J&J's trailing P/E near 39 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.71 of EPS for 2027) the multiple is near 22. That is a premium to where the stock traded early in 2026, after a roughly 24% year-to-date rise, and the dividend yield has compressed to about 2.1%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of October 16, 2026.
Headline figures (approximate, October 2026): DNTH shows revenue (ttm) ~$1.9M (license and collaboration income; no product sales), net loss (ttm) ~$192M; Q2 2026 loss ~$50M, EPS -$0.90 vs -$0.91 consensus, market cap ~$3.9B at a $71.38 close on Oct 16, 2026, cash ~$887M at June 30, 2026 per Yahoo Finance; company cites ~$1.1-1.2B and runway into 2030; JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~25%.
The bottom line: DNTH vs JNJ
DNTH and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DNTH and JNJ exposure against your real portfolio. It is not an investment adviser.
Wondering how DNTH or JNJ fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Dianthus Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how DNTH fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between DNTH and JNJ?
+
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing claseprubart (DNTH103), an antibody that selectively blocks the active form of the C1s enzyme in the complement system's classical pathway while leaving the alternative and lectin pathways intact to preserve immune defense. Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DNTH or JNJ the better stock?
+
Neither is universally better. JNJ is the larger incumbent; DNTH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DNTH or JNJ?
+
On forward P/E (as of October 2026), DNTH trades at -15.63x and JNJ at 21.83x, so DNTH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DNTH and JNJ?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DNTH vs JNJ?
+
DNTH: As a pre-revenue, essentially single-asset company, DNTH faces concentrated clinical risk: a failed or ambiguous Phase 3 readout in CIDP or gMG could sharply reduce the value of the entire pipeline. The complement and neuromuscular space is crowded with well-capitalized competitors including argenx, UCB, and AstraZeneca's Alexion, so even successful approval would face commercial and pricing pressure. The company is not yet profitable and continues to burn cash on multiple late-stage trials, and dilution is already happening: after an upsized raise earlier in the year, Dianthus filed a further $500 million follow-on offering in September 2026. Losses are widening too, to about $192 million over the twelve months to June 2026 from about $85 million in calendar 2024. Regulatory outcomes, safety findings, and the durability of the convenience advantage all remain unproven at scale. After a run of roughly 7x off its lows, the stock has shown how sharply sentiment can reverse, falling about 26% in the month to October 16, 2026. JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. International pricing pressure weighed on third-quarter 2026 results, and large items outside adjusted earnings cut GAAP net income to about $210 million that quarter. Growth is steady rather than rapid, yet after a roughly 34% one-year rise the stock trades near 22 times forward earnings, so valuation now leaves less cushion than it did when J&J traded in the mid-teens.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DNTH or JNJ; figures are approximate and dated (as of October 2026). Verify current data before investing.